EVMN
Evommune, Inc.NYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$823.74M
P/E Ratio
—
EPS
$-2.11
Beta
—
52W High
$33.20
52W Low
$13.88
50-Day MA
$24.25
200-Day MA
$22.10
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Evommune, Inc.
Evommune, Inc. is a forward-thinking biotechnology firm dedicated to advancing innovative therapeutics for immunological disorders, addressing critical unmet medical needs. The company boasts a promising pipeline and utilizes state-of-the-art research methodologies to optimize immune response and improve patient outcomes. It aims to establish itself as a leader in the dynamic immunotherapy landscape through rigorous scientific practices and strategic collaborations. As Evommune advances its clinical trials, it seeks to offer groundbreaking solutions that may redefine care standards in the field of immunology, ultimately enhancing the quality of life for patients.
Fundamentals
| Revenue (TTM) | $10.00M |
| Gross Profit (TTM) | $10.00M |
| EBITDA | $-88.63M |
| Operating Margin | -900.00% |
| Return on Equity | -45.00% |
| Return on Assets | -29.70% |
| Revenue/Share (TTM) | $0.71 |
| Book Value | $8.46 |
| Price-to-Book | 2.71 |
| Price-to-Sales (TTM) | 82.37 |
| EV/Revenue | 62.08 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $36.02M |
| Float | $19.96M |
| % Insiders | 7.98% |
| % Institutions | 110.45% |
Historical Volatility
HV 10-Day
58.52%
HV 20-Day
56.21%
HV 30-Day
53.10%
HV 60-Day
72.27%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($52.25 target)
2
Strong Buy8
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026